TOLMAR Pharmaceuticals Champions Prostate Cancer Awareness Month

LINCOLNSHIRE, Ill. and FT. COLLINS, Colo., Sept. 7, 2017 /PRNewswire/ -- TOLMAR Pharmaceuticals, Inc., a fully integrated specialty pharmaceutical company, joins the prostate cancer community in marking Prostate Cancer Awareness Month and supporting the millions of men living with the condition (GLOBOCAN 2012 (IARC), 2017). Recognized each year throughout the month of September, Prostate Cancer Awareness Month is intended to raise awareness of prostate cancer and its impact on patients, caregivers and providers while encouraging screening and raising funds for research and education.

"TOLMAR is proud to support patients, advocacy groups, physicians and researchers in the fight against prostate cancer," said Susan Rodriguez, CEO, TOLMAR Pharmaceuticals. "By sponsoring and participating in awareness events, we aim to bring attention to the importance of prevention, screening and early diagnosis, as well as to raise funds for research."

TOLMAR is supporting more than 25 events in its headquarters markets and across the U.S. in September including:

• Blue Shoe Run, Sept. 9, Denver, Colo.: More than 50 employees and family members of TOLMAR will participate to benefit The Urology Center of Colorado Foundation (TUCC)
• Northern Colorado Prostate Cancer Golf Invitational, Sept. 9, Loveland, Colo.: Sponsoring the event and more than 25 employees to participate and raise funds for the Prostate Cancer Foundation
• SEA Blue Prostate Cancer Walk/Run, Sept. 10, Chicago, IL.: Sponsorship and employee participation to benefit UsTOO prostate cancer education and support services
• ZERO Prostate Cancer Run/Walk: Sponsorship and participation in 16 events from San Diego to Boston to benefit ZERO – The End of Prostate Cancer and local non-profit foundations

"With prostate cancer affecting one in every seven men in the U.S. at some time in their lives (American Cancer Society, 2017), each of us has friends or loved ones who have been impacted by this devastating disease," said Mike Duncan, CEO, TOLMAR Inc. "Participation in Prostate Cancer Awareness Month also honors the memories of those who have succumbed and recognizes their loss."

About TOLMAR and ELIGARD

TOLMAR is a fully integrated pharmaceutical company focused on the innovative development, approval, manufacturing and commercialization of specialty pharmaceuticals. The Company's lead product, ELIGARD®, is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

"TOLMAR" refers to TOLMAR Holding, Inc. and its wholly owned operating subsidiaries, TOLMAR Inc., TOLMAR Therapeutics, Inc., and TOLMAR Pharmaceuticals, Inc. ELIGARD was developed and is manufactured by TOLMAR Inc. TOLMAR global headquarters, product development and manufacturing facilities are based in northern Colorado, while TOLMAR Pharmaceuticals' U.S. commercial business is based in Lincolnshire, Illinois. For more information about the company, please visit www.TOLMAR.com. Information about ELIGARD is available at www.eligard.com.

Important Safety Information for ELIGARD® (leuprolide acetate for injectable suspension)

ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature. ELIGARD is also contraindicated in women who are pregnant or may become pregnant. Expected hormonal changes that occur with ELIGARD treatment increase the risk for pregnancy loss and fetal harm when administered to a pregnant woman.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH analogs. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH analogs in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

See package insert for full prescribing and safety information.

SOURCE TOLMAR Pharmaceuticals, Inc.

Related Links

http://www.TOLMAR.com